You are here: Industry Insights > ocular

News List

Ocular Therapeutix Announces Termination of the Collaboration with Regeneron to Develop a Sustained-Release Formulation of Aflibercept for the Treatment of Wet AMD and other Serious Retinal Diseases firstwordpharma
August 06, 2021
Ocular Therapeutix, Inc. (NASDAQ:OCUL) today announced that Regeneron has terminated the option and license agreement collaboration between the companies.
Rate of Opioid Rx Increasing for Incisional Ocular Surgery drugs
September 23, 2019
The rate of filled opioid prescriptions is increasing for all types of incisional ocular surgery, according to a study published online Sept. 19 in JAMA Ophthalmology.
Ocular Therapeutix Announces FDA Approval of Dextenza (dexamethasone intracanalicular insert) for the Treatment of Ocular Inflammation Following Ophthalmic Surgery drugs
June 25, 2019
Ocular Therapeutix Announces FDA Approval of Dextenza (dexamethasone intracanalicular insert) for the Treatment of Ocular Inflammation Following Ophthalmic Surgery.
Ocular Therapeutix Announces Topline Results of Phase 3 Clinical Trial of OTX-TP for the Treatment of Glaucoma drugs
May 22, 2019
Ocular Therapeutix Announces Topline Results of Phase 3 Clinical Trial of OTX-TP for the Treatment of Glaucoma.